Uniquely, Cergentis’ TLA technology enables deep sequencing and detection of all structural and sequence variation in genes of interest.


The TLA technology is therefore ideally suited to identify all gene fusions and other clinically relevant mutations in oncogenes.


Because TLA analyses just require the design of one locus-specific primer pair, TLA analyses can be applied to perform targeted sequencing of individual loci in individual samples. TLA analyses can also be multiplexed and applied in routine analyses of multiple genes.


Please select the appropriate application in the menu on the left.



© 2012-2018 Cergentis B.V. All rights reserved.